Skip to main content

Peer Review reports

From: The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations

Original Submission
25 Mar 2017 Submitted Original manuscript
7 May 2017 Reviewed Reviewer Report - Dereje Nigussie Woldemichael
9 May 2017 Reviewed Reviewer Report - Esther Black
11 May 2017 Reviewed Reviewer Report - Barbara Wiśniowska
22 May 2017 Author responded Author comments - chih-jen yang
Resubmission - Version 2
22 May 2017 Submitted Manuscript version 2
30 May 2017 Reviewed Reviewer Report - Esther Black
31 May 2017 Reviewed Reviewer Report - Barbara Wiśniowska
19 Jun 2017 Author responded Author comments - chih-jen yang
Resubmission - Version 3
19 Jun 2017 Submitted Manuscript version 3
31 Jul 2017 Author responded Author comments - chih-jen yang
Resubmission - Version 4
31 Jul 2017 Submitted Manuscript version 4
Publishing
5 Dec 2017 Editorially accepted
13 Dec 2017 Article published 10.1186/s40360-017-0190-1

You can find further information about peer review here.

Back to article page